On June 10th, AUSNUTRIA (01717) spent HKD 22,000 to repurchase 15,000 shares.
Ausnutria (01717) announced that on June 10, 2026, the company spent HKD 22,000 to repurchase 15,000 shares, with a repurchase price of HKD 1.47-1.49 per share.
AUSNUTRIA (01717) announced on June 10, 2026, that the company will spend 22,000 Hong Kong dollars to repurchase 15,000 shares of its stock, with a repurchase price of 1.47-1.49 Hong Kong dollars per share.
Related Articles
SIPAI HEALTH (00314) repurchased 200,000 shares at a cost of approximately HKD 240,200 on June 10th.
ALPHAMAB-B(09966): The phase III clinical study of Anituximab (KN026) as first-line treatment for HER2-positive advanced breast cancer has reached the primary endpoint.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
SIPAI HEALTH (00314) repurchased 200,000 shares at a cost of approximately HKD 240,200 on June 10th.
ALPHAMAB-B(09966): The phase III clinical study of Anituximab (KN026) as first-line treatment for HER2-positive advanced breast cancer has reached the primary endpoint.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
RECOMMEND
